{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:20:44Z","timestamp":1782890444647,"version":"3.54.5"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1097\/crd.0000000000000031","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T10:27:32Z","timestamp":1402655252000},"page":"11-17","source":"Crossref","is-referenced-by-count":12,"title":["Cardiovascular Disease and Hepatitis C Virus Infection"],"prefix":"10.1097","volume":"23","author":[{"given":"Vasiliki","family":"Katsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Felekos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Skevofilax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantina","family":"Aggeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Tousoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christodoulos","family":"Stefanadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kallikazaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.3748\/wjg.v19.i44.7896","article-title":"An insight into the diagnosis and pathogenesis of hepatitis C virus infection.","volume":"19","author":"Irshad","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"740138","DOI":"10.1155\/2012\/740138","article-title":"Morphologic features of extrahepatic manifestations of hepatitis C virus infection.","volume":"2012","author":"Ko","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.dld.2006.06.008","article-title":"Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach.","volume":"39","author":"Zignego","year":"2007","journal-title":"Dig Liver Dis"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4254\/wjh.v5.i10.528","article-title":"Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations.","volume":"5","author":"Zampino","year":"2013","journal-title":"World J Hepatol"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1053\/j.gastro.2006.03.014","article-title":"HCV Meta-Analysis (on) Individual Patients Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.","volume":"130","author":"Leandro","year":"2006","journal-title":"Gastroenterology"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/599371","article-title":"Hepatitis C virus infection and the risk of coronary disease.","volume":"49","author":"Butt","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1253\/circj.CJ-08-0459","article-title":"Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system.","volume":"72","author":"Alyan","year":"2008","journal-title":"Circ J"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/apt.12234","article-title":"Associations of chronic hepatitis C with metabolic and cardiac outcomes.","volume":"37","author":"Younossi","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cgh.2013.05.008","article-title":"Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C.","volume":"12","author":"Coppola","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.4049\/jimmunol.0902038","article-title":"Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage.","volume":"183","author":"Sansonno","year":"2009","journal-title":"J Immunol"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.amjcard.2012.09.028","article-title":"Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis.","volume":"111","author":"Terrier","year":"2013","journal-title":"Am J Cardiol"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0098-2997(00)00004-2","article-title":"Pathogenesis of liver fibrosis: role of oxidative stress.","volume":"21","author":"Poli","year":"2000","journal-title":"Mol Aspects Med"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/hrt.2003.018937","article-title":"Evidence for association between hepatitis C virus seropositivity and coronary artery disease.","volume":"90","author":"Vassalle","year":"2004","journal-title":"Heart"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1161\/01.HYP.0000154229.97341.d2","article-title":"Evaluation of carotid-femoral pulse wave velocity: influence of timing algorithm and heart rate.","volume":"45","author":"Millasseau","year":"2005","journal-title":"Hypertension"},{"key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0021-9150(02)00388-X","article-title":"Hepatitis C virus seropositivity, but not hepatitis B virus carrier or seropositivity, associated with increased pulse wave velocity.","volume":"166","author":"Tomiyama","year":"2003","journal-title":"Atherosclerosis"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","article-title":"Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.","volume":"42","author":"Cacoub","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/gut.2009.202317","article-title":"Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors.","volume":"59","author":"Mostafa","year":"2010","journal-title":"Gut"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0b013e32832d7aa8","article-title":"Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the womens interagency HIV study.","volume":"23","author":"Tien","year":"2009","journal-title":"AIDS"},{"key":"R20-2-20210203","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","article-title":"Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.","volume":"134","author":"Moucari","year":"2008","journal-title":"Gastroenterology"},{"key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jhep.2008.08.006","article-title":"Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.","volume":"49","author":"White","year":"2008","journal-title":"J Hepatol"},{"key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/hep.27047","article-title":"The Relationship of Hepatitis C Virus Infection with Diabetes in the United States Population.","volume":"60","author":"Ruhl","year":"2014","journal-title":"Hepatology"},{"key":"R23-2-20210203","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3748\/wjg.v18.i3.212","article-title":"Hepatitis C virus induced insulin resistance impairs response to anti viral therapy.","volume":"18","author":"El-Zayadi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R24-2-20210203","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0002-9440(10)63408-6","article-title":"Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3.","volume":"165","author":"Kawaguchi","year":"2004","journal-title":"Am J Pathol"},{"key":"R25-2-20210203","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.21634","article-title":"The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms.","volume":"45","author":"Pazienza","year":"2007","journal-title":"Hepatology"},{"key":"R26-2-20210203","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/JVI.01672-07","article-title":"Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream aktprotein kinase B signaling pathway for insulin resistance.","volume":"82","author":"Banerjee","year":"2008","journal-title":"J Virol"},{"key":"R27-2-20210203","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1128\/JVI.00050-12","article-title":"Hepatitis C virus activates the mTORS6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance.","volume":"86","author":"Bose","year":"2012","journal-title":"J Virol"},{"key":"R28-2-20210203","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jhep.2007.11.022","article-title":"Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.","volume":"48","author":"Romero-Gomez","year":"2008","journal-title":"J Hepatol"},{"key":"R30-2-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/CIRCOUTCOMES.110.957415","article-title":"Veterans Aging Cohort Study. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C.","volume":"4","author":"Freiberg","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R31-2-20210203","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijcard.2011.07.016","article-title":"Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study.","volume":"164","author":"Oliveira","year":"2013","journal-title":"Int J Cardiol"},{"key":"R32-2-20210203","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/3-540-30822-9_7","article-title":"Role of hepatitis C virus in cardiomyopathies.","volume":"55","author":"Matsumori","year":"2006","journal-title":"Ernst Schering Res Found Workshop"},{"key":"R33-2-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cardfail.2005.11.004","article-title":"Myocarditis and heart failure associated with hepatitis C virus infection.","volume":"12","author":"Matsumori","year":"2006","journal-title":"J Card Fail"},{"key":"R34-2-20210203","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2169\/internalmedicine.40.78","article-title":"Hepatitis C virus and cardiomyopathy.","volume":"40","author":"Matsumori","year":"2001","journal-title":"Intern Med"},{"key":"R35-2-20210203","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/hrt.80.3.270","article-title":"Idiopathic dilated cardiomyopathy: lack of association with hepatitis C virus infection.","volume":"80","author":"Dalekos","year":"1998","journal-title":"Heart"},{"key":"R36-2-20210203","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1590\/S1413-86702007000300004","article-title":"Prevalence of hepatitis C and B virus infection in patients with idiopathic dilated cardiomyopathy in Brazil: a pilot study.","volume":"11","author":"Reis","year":"2007","journal-title":"Braz J Infect Dis"},{"key":"R37-2-20210203","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/labinvest.3780120","article-title":"Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy.","volume":"80","author":"Matsumori","year":"2000","journal-title":"Lab Invest"},{"key":"R38-2-20210203","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM199508033330501","article-title":"A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.","volume":"333","author":"Mason","year":"1995","journal-title":"N Engl J Med"},{"key":"R39-2-20210203","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/01.RES.0000156077.54903.67","article-title":"Hepatitis C virus infection and cardiomyopathies.","volume":"96","author":"Matsumori","year":"2005","journal-title":"Circ Res"},{"key":"R41-2-20210203","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2893.2009.01237.x","article-title":"High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C.","volume":"17","author":"Antonelli","year":"2010","journal-title":"J Viral Hepat"},{"key":"R42-2-20210203","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2893.2011.01551.x","article-title":"Increased serum N-terminal pro-B-type natriuretic peptide and left ventricle diastolic dysfunction in patients with hepatitis C virus infection.","volume":"19","author":"Che","year":"2012","journal-title":"J Viral Hepat"},{"key":"R43-2-20210203","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/SMJ.0b013e31822462e2","article-title":"Effect of hepatitis C virus infection on the left ventricular systolic and diastolic functions.","volume":"104","author":"Demir","year":"2011","journal-title":"South Med J"},{"key":"R44-2-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2012.07.045","article-title":"Myocardial injury in patients with chronic hepatitis C infection.","volume":"58","author":"Maruyama","year":"2013","journal-title":"J Hepatol"},{"key":"R45-2-20210203","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.healun.2011.06.003","article-title":"Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity.","volume":"30","author":"Lee","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R46-2-20210203","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.transproceed.2012.03.024","article-title":"The outcome of heart transplantation in hepatitis C-positive recipients.","volume":"44","author":"Lin","year":"2012","journal-title":"Transplant Proc"},{"key":"R47-2-20210203","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0041-1345(96)00312-0","article-title":"Outcomes of hepatitis C positive (HCV) heart transplant recipients.","volume":"29","author":"Lake","year":"1997","journal-title":"Transplant Proc"},{"key":"R48-2-20210203","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1034\/j.1600-6143.2002.20508.x","article-title":"Hepatitis C-positive donors in heart transplantation.","volume":"2","author":"Marelli","year":"2002","journal-title":"Am J Transplant"},{"key":"R49-2-20210203","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.510300519","article-title":"Outcome of de novo hepatitis C virus infection in heart transplant recipients.","volume":"30","author":"Ong","year":"1999","journal-title":"Hepatology"},{"key":"R50-2-20210203","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/jama.296.15.1843","article-title":"Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients.","volume":"296","author":"Gasink","year":"2006","journal-title":"JAMA"},{"key":"R51-2-20210203","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/clc.20764","article-title":"Major adverse cardiac events in patients with hepatitis C infection treated with bare-metal versus drug-eluting stents.","volume":"33","author":"Palaniswamy","year":"2010","journal-title":"Clin Cardiol"},{"key":"R52-2-20210203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.transproceed.2010.09.096","article-title":"Outcome of treatment with pegylated interferon and ribavirin in heart transplant recipients with chronic hepatitis C.","volume":"43","author":"Durante-Mangoni","year":"2011","journal-title":"Transplant Proc"},{"key":"R53-2-20210203","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10620-009-0959-1","article-title":"Statin therapy and serum transaminases among a cohort of HCV-infected veterans.","volume":"55","author":"Henderson","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R54-2-20210203","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.amjcard.2005.06.071","article-title":"Experience with statin use in patients with chronic hepatitis C infection.","volume":"96","author":"Gibson","year":"2005","journal-title":"Am J Cardiol"},{"key":"R55-2-20210203","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1592\/phco.27.6.845","article-title":"Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.","volume":"27","author":"Segarra-Newnham","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R57-2-20210203","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0168-8278(03)00051-5","article-title":"Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells.","volume":"38","author":"Rombouts","year":"2003","journal-title":"J Hepatol"},{"key":"R58-2-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.molcel.2005.04.004","article-title":"Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication.","volume":"18","author":"Wang","year":"2005","journal-title":"Mol Cell"},{"key":"R59-2-20210203","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/hep.22865","article-title":"HALT-C Trial Group. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.","volume":"49","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"R60-2-20210203","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bjc.6601566","article-title":"Statin use and cancer risk in the General Practice Research Database.","volume":"90","author":"Kaye","year":"2004","journal-title":"Br J Cancer"},{"key":"R61-2-20210203","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cmet.2013.12.010","article-title":"NCOA5, IL-6, type 2 diabetes, and HCC: The deadly quartet.","volume":"19","author":"Dhar","year":"2014","journal-title":"Cell Metab"},{"key":"R62-2-20210203","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","article-title":"Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes.","volume":"136","author":"El-Serag","year":"2009","journal-title":"Gastroenterology"},{"key":"R63-2-20210203","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/CS20120594","article-title":"Amiodarone inhibits the entry and assembly steps of hepatitis C virus life cycle.","volume":"125","author":"Cheng","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"R64-2-20210203","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1253\/circj.66.1161","article-title":"Arrhythmogenic and inotropic effects of interferon investigated in perfused and in vivo rat hearts: influences of cardiac hypertrophy and isoproterenol.","volume":"66","author":"Odashiro","year":"2002","journal-title":"Circ J"},{"key":"R66-2-20210203","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C.","volume":"368","author":"Poordad","year":"2013","journal-title":"N Engl J Med"},{"key":"R67-2-20210203","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hep.27053","article-title":"All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection.","volume":"60","author":"Wyles","year":"2014","journal-title":"Hepatology"},{"key":"R69-2-20210203","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1128\/AAC.00653-11","article-title":"Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:49:16Z","timestamp":1620949756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201501000-00002"}},"subtitle":["An Irrelevant Statement or a Hot Relationship?"],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000031","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}